Search

Your search keyword '"Kalaycio M"' showing total 704 results
Start Over Author "Kalaycio M"
704 results on '"Kalaycio M"'

1. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Author

Bühler, A, Wendtner, C-M, Kipps, TJ, Rassenti, L, Fraser, GAM, Michallet, A-S, Hillmen, P, Dürig, J, Gregory, SA, Kalaycio, M, Aurran-Schleinitz, T, Trentin, L, Gribben, JG, Chanan-Khan, A, Purse, B, Zhang, J, De Bedout, S, Mei, J, Hallek, M, and Stilgenbauer, S

Subjects
Humans, Recurrence, Thalidomide, Antineoplastic Agents, Immunologic Factors, Prognosis, Treatment Outcome, Retreatment, Survival Analysis, Follow-Up Studies, Drug Resistance, Neoplasm, Mutation, Aged, Aged, 80 and over, Middle Aged, Female, Immunoglobulin Heavy Chains, Male, Tumor Suppressor Protein p53, Leukemia, Lymphocytic, Chronic, B-Cell, Lenalidomide, Drug Resistance, Neoplasm, and over, Leukemia, Lymphocytic, Chronic, B-Cell, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis
Abstract

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR) was 40.4% (42/104). ORRs were similar irrespective of TP53 mutation (36.1% (13/36) vs 43.3% (26/60) for patients with vs without mutation) or IGHV mutation status (45.0% (9/20) vs 39.1% (27/68)); however, patients with del(17p) had lower ORRs than those without del(17p) (21.7% (5/22) vs 47.1% (33/70); P=0.049). No significant differences in progression-free survival and overall survival (OS) were observed when comparing subgroups defined by the presence or absence of high-risk genetic characteristics. In multivariate analyses, only multiple prior therapies (⩾3 lines) significantly impacted outcomes (median OS: 21.2 months vs not reached; P=0.019). This analysis indicates that lenalidomide is active in patients with relapsed/refractory CLL with unfavorable genetic profiles, including TP53 inactivation or unmutated IGHV. (ClinicalTrials.gov identifier: NCT00963105).

Published
2016

2. Clinical Outcomes of Image-Guided Volumetric Modulated Arc Therapy for Total Body Irradiation

Author

Kilic, S.S., primary, Halima, A., additional, Zhang, Z., additional, Cho, Y.B., additional, Magnelli, A., additional, Kalaycio, M., additional, Sauter, C.S., additional, Sobecks, R., additional, Hamilton, B., additional, Rotz, S.J., additional, Hanna, R., additional, Murphy, E.S., additional, Cherian, S., additional, Xia, P., additional, and Guo, B., additional

Published
2023
Full Text
View/download PDF

8. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

Author

Uy, G L, Costa, L J, Hari, P N, Zhang, M-J, Huang, J-X, Anderson, K C, Bredeson, C N, Callander, N S, Cornell, R F, Perez, M A D, Dispenzieri, A, Freytes, C O, Gale, R P, Garfall, A, Gertz, M A, Gibson, J, Hamadani, M, Lazarus, H M, Kalaycio, M E, Kamble, R T, Kharfan-Dabaja, M A, Krishnan, A Y, Kumar, S K, Kyle, R A, Landau, H J, Lee, C H, Maiolino, A, Marks, D I, Mark, T M, Munker, R, Nishihori, T, Olsson, R F, Ramanathan, M, Rodriguez, T E, Saad, A A, Savani, B N, Schiller, G J, Schouten, H C, Schriber, J R, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, E A, Tay, J, To, L B, Vesole, D H, Vogl, D T, Wagner, J L, Wirk, B, Wood, W A, and D'Souza, A

Published
2015
Full Text
View/download PDF

19. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, Saber, W, Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, and Saber, W

Published
2021

20. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

Author

Mahindra, A, Kalaycio, M E, Vela-Ojeda, J, Vesole, D H, Zhang, M-J, Li, P, Berenson, J R, Bird, J M, Dispenzieri, A, Gajewski, J L, Gale, R P, Holmberg, L, Kumar, S, Kyle, R A, Lazarus, H M, Lonial, S, Mikhael, J, Milone, G A, Munker, R, Nath, R, Saccaro, S, To, L Bik, Vogl, D T, Wirk, B, and Hari, P

Published
2012
Full Text
View/download PDF

40. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Author

DeFilipp, Z, Ancheta, R, Liu, Y, Hu, Z-H, Gale, RP, Snyder, D, Schouten, HC, Kalaycio, M, Hildebrandt, GC, Ustun, C, Daly, A, Ganguly, S, Inamoto, Y, Litzow, M, Szer, J, Savoie, ML, Hossain, N, Kharfan-Dabaja, MA, Hamadani, M, Reshef, R, Bajel, A, Schultz, KR, Gadalla, S, Gerds, A, Liesveld, J, Juckett, MB, Kamble, R, Hashmi, S, Abdel-Azim, H, Solh, M, Bacher, U, Lazarus, H, Olsson, R, Cahn, J-Y, Grunwald, MR, Savani, BN, Yared, J, Rowe, JM, Cerny, J, Chaudhri, NA, Aljurf, M, Beitinjaneh, A, Seo, S, Nishihori, T, Hsu, JW, Ramanathan, M, Alyea, E, Popat, U, Sobecks, R, Saber, W, DeFilipp, Z, Ancheta, R, Liu, Y, Hu, Z-H, Gale, RP, Snyder, D, Schouten, HC, Kalaycio, M, Hildebrandt, GC, Ustun, C, Daly, A, Ganguly, S, Inamoto, Y, Litzow, M, Szer, J, Savoie, ML, Hossain, N, Kharfan-Dabaja, MA, Hamadani, M, Reshef, R, Bajel, A, Schultz, KR, Gadalla, S, Gerds, A, Liesveld, J, Juckett, MB, Kamble, R, Hashmi, S, Abdel-Azim, H, Solh, M, Bacher, U, Lazarus, H, Olsson, R, Cahn, J-Y, Grunwald, MR, Savani, BN, Yared, J, Rowe, JM, Cerny, J, Chaudhri, NA, Aljurf, M, Beitinjaneh, A, Seo, S, Nishihori, T, Hsu, JW, Ramanathan, M, Alyea, E, Popat, U, Sobecks, R, and Saber, W

Abstract

It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML who underwent transplantation between 2007 and 2014 and received maintenance TKI following HCT (n = 89) compared with no TKI maintenance (n = 301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy before HCT. The majority of patients had a disease status of first chronic phase at HCT (n = 240; 62%). The study was conducted as a landmark analysis, excluding patients who died, relapsed, had chronic graft-versus-host disease, or were censored before day +100 following HCT. Of the 89 patients who received TKI maintenance, 77 (87%) received a single TKI and the other 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n = 50), imatinib (n = 27), and nilotinib (n = 27). As measured from day +100, the adjusted estimates for 5-year relapse (maintenance, 35% versus no maintenance, 26%; P = .11), leukemia-free survival (maintenance, 42% versus no maintenance, 44%; P = .65), or overall survival (maintenance, 61% versus no maintenance, 57%; P = .61) did not differ significantly between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by disease status before transplantation. In conclusion, our data from this day +100 landmark analysis do not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes. The optimal approach to TKI administration in the post-transplantation setting in patients with CML remains undetermined.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results